[Relationship between genetic polymorphism of NAT2 and susceptibility to urinary bladder cancer].
OBJECTIVE
To study the relationship between genetic polymorphism of NAT2 and susceptibility to bladder cancer.


METHODS
NAT2 genotypes were determined by PCR-RFLP method in 69 patients with bladder transitional cell carcinoma and 88 healthy controls.


RESULTS
The frequency of NAT2 slow genotypes was 26.1% (18/69) in patients compared with 14.8% (13/88) in controls (P < 0.05). Bladder cancer risk in patients with NAT2 slow genotypes was 2 fold as high as that in patients with NAT2 rapid genotypes. When NAT2 rapid genotypes/non-smoker were used as reference, bladder cancer risk increased to 5.8-fold (P < 0.05). Among the smokers with PY higher than 10, the patients showed a higher frequency of NAT2 slow genotype than controls (P < 0.05). It was also shown that the patients with slow NAT2 genotypes were more likely to have high grade tumor (P < 0.05) and advanced stage tumor (P < 0.01).


CONCLUSIONS
The results suggest that NAT2 genetic polymorphism is associated with bladder cancer susceptibility. People with NAT2 slow genotype have higher bladder cancer risk.
Hao
Gang-yue
GY
Department of Urology, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing 100050, China. haogangyue@hotmail.com
Zhang
Wei-dong
WD
Chen
Yong-he
YH
Zhang
Dao-xin
DX
Zhang
Yu-hai
YH
D001191:Arylamine N-Acetyltransferase / Q000235:genetics*; D002295:Carcinoma, Transitional Cell / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D012907:Smoking; D001749:Urinary Bladder Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology
D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human